首页>
外国专利>
COMBINATION THERAPY WITH T-CELL REDIRECTING BISPECIFIC ANTIBODIES AND CHECKPOINT INHIBITORS
COMBINATION THERAPY WITH T-CELL REDIRECTING BISPECIFIC ANTIBODIES AND CHECKPOINT INHIBITORS
展开▼
机译:联合治疗与T细胞重定向双特异性抗体和检查点抑制剂
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for a tumor-associated antigen (TAA) and at least one binding site for an antigen expressed on an effector T cell, NK cell, monocyte or neutrophil. The bispecific antibodies are of use for inducing an immune response against a TAA-expressing tumor. The methods may comprising administering the bispecific antibody in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC. In preferred embodiments, the checkpoint inhibitor is a chimeric or humanized anti-PD1 antibody as described herein.
展开▼